Various therapeutic drug molecules have been studied to evaluate their efficacies against different types of cancer including NSCLC by modulating the expression of survivin, hif-1α and p27KIP1 (Choi et al., 2009[2]; Li et al., 2019[11]; Naruse et al., 2000[13]). Here, CDKN1B is linked to non-small cell lung carcinoma.